Skip to content

Attractive Prices And Plenty Of Upside Make These 2 “Cutting Edge” Cancer Stocks Potential Buys

In the cancer treatment space, today’s article highlights two small-cap biotech names to consider this month based on their attractive prices and potential to “take the oncology market by storm.” As the author explains, “Both companies have first-in-class therapies at the cutting edge of science. One company received approval from the Food and Drug Administration (FDA) for its cancer drug and is expanding to other indications. Another offers a promising pipeline with a strong patent portfolio that is in the process of regulatory submission.” For more, CLICK HERE.